Research Roundup: Engineered Nanoparticles and New Potential Standards of Care
Positive results from a phase 3 trial of Astellas Pharmaceuticals’ zolbetuximab and modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) “may represent a... Read More
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.
Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
In a phase 2 trial in advanced gastric cancer with high expression of CLDN18.2, adding Ganymed Pharmaceuticals’experimental drug zolbetuximab to chemotherapy improved... Read More
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma
Adding Herceptin to chemotherapy improved outcomes for patients with HER2-positive advanced gastric cancer in a clinical trial.
Bemarituzumab Improves Gastric Cancer Survival Response Rates
In a study presented at ASCO GI, adding Five Prime’s experimental targeted drug to a modified FOLFOX chemotherapy regimen significantly improved survival... Read More
Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis
A study found that “cytoreductive” surgery combined with intraperitoneal chemotherapy improved survival for some gastric cancer patients but that the strategy should... Read More
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Immunotherapy for stomach cancer may work better if the therapy is delivered earlier in the course of disease and in combination with... Read More
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer
Chemotherapy after surgery for gastric cancer was superior to chemoradiation in a recent trial.
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.